Difference between revisions of "Rituximab and hyaluronidase human (Rituxan Hycela)"
Jump to navigation
Jump to search
m (Jwarner moved page Rituximab and hyaluronidase human (Rituximab Hycela) to Rituximab and hyaluronidase human (Rituxan Hycela): Clarified brand name) |
Warner-admin (talk | contribs) m (Text replacement - "Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL)" to "Chronic lymphocytic leukemia (CLL/SLL)") |
||
| Line 7: | Line 7: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
| − | *[[Chronic lymphocytic leukemia (CLL | + | *[[Chronic lymphocytic leukemia (CLL/SLL)]] |
*[[Diffuse large B-cell lymphoma]] | *[[Diffuse large B-cell lymphoma]] | ||
*[[Follicular lymphoma]] | *[[Follicular lymphoma]] | ||
| Line 15: | Line 15: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | *6/22/2017: [https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm564235.htm FDA approved] for adult patients with [[follicular lymphoma]], [[diffuse large B-cell lymphoma]], and [[Chronic lymphocytic leukemia (CLL | + | *6/22/2017: [https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm564235.htm FDA approved] for adult patients with [[follicular lymphoma]], [[diffuse large B-cell lymphoma]], and [[Chronic lymphocytic leukemia (CLL/SLL)|chronic lymphocytic leukemia]], as follows: |
**Relapsed or refractory, [[Follicular lymphoma|follicular lymphoma (FL)]] as a single agent. | **Relapsed or refractory, [[Follicular lymphoma|follicular lymphoma (FL)]] as a single agent. | ||
**Previously untreated [[Follicular lymphoma|FL]] in combination with first line chemotherapy and, in patients achieving a complete or partial response to rituximab in combination with chemotherapy, as single-agent maintenance therapy. | **Previously untreated [[Follicular lymphoma|FL]] in combination with first line chemotherapy and, in patients achieving a complete or partial response to rituximab in combination with chemotherapy, as single-agent maintenance therapy. | ||
**Non-progressing (including stable disease), [[Follicular lymphoma|FL]] as a single agent after first-line [[Follicular_lymphoma#CVP|cyclophosphamide, vincristine, and prednisone (CVP)]] chemotherapy. | **Non-progressing (including stable disease), [[Follicular lymphoma|FL]] as a single agent after first-line [[Follicular_lymphoma#CVP|cyclophosphamide, vincristine, and prednisone (CVP)]] chemotherapy. | ||
**Previously untreated [[Diffuse large B-cell lymphoma|diffuse large B-cell lymphoma (DLBCL)]] in combination with cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) or other anthracycline-based chemotherapy regimens. | **Previously untreated [[Diffuse large B-cell lymphoma|diffuse large B-cell lymphoma (DLBCL)]] in combination with cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) or other anthracycline-based chemotherapy regimens. | ||
| − | **Previously untreated and previously treated [[Chronic lymphocytic leukemia (CLL | + | **Previously untreated and previously treated [[Chronic lymphocytic leukemia (CLL/SLL)|CLL]] in combination with fludarabine and cyclophosphamide (FC). |
**Rituxan Hycela is not indicated for the treatment of non-malignant conditions. | **Rituxan Hycela is not indicated for the treatment of non-malignant conditions. | ||
| Line 35: | Line 35: | ||
[[Category:Anti-CD20 antibodies]] | [[Category:Anti-CD20 antibodies]] | ||
| − | [[Category:Chronic lymphocytic leukemia (CLL | + | [[Category:Chronic lymphocytic leukemia (CLL/SLL) medications]] |
[[Category:Diffuse large B-cell lymphoma medications]] | [[Category:Diffuse large B-cell lymphoma medications]] | ||
[[Category:Follicular lymphoma medications]] | [[Category:Follicular lymphoma medications]] | ||
[[Category:Drugs FDA approved in 2017]] | [[Category:Drugs FDA approved in 2017]] | ||
Revision as of 15:02, 14 October 2017
General information
Class/mechanism: Anti-CD20 antibody, chimeric murine/human monoclonal IgG1 kappa, which binds to CD20 (human B-lymphocyte-restricted differentiation antigen, Bp35), which is expressed on B-cells. The Fc domain recruits immune effector functions to mediate B-cell lysis. Possible mechanisms of cell lysis include complement-dependent cytotoxicity (CDC) and antibody-dependent cell mediated cytotoxicity (ADCC).
Route: SC* (Rituxan Hycela treatment should be initiated only after patients have received at least one full dose of a rituximab product by intravenous infusion)
Extravasation: neutral
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.
Diseases for which it is used
Patient drug information
To be completed
History of changes in FDA indication
- 6/22/2017: FDA approved for adult patients with follicular lymphoma, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia, as follows:
- Relapsed or refractory, follicular lymphoma (FL) as a single agent.
- Previously untreated FL in combination with first line chemotherapy and, in patients achieving a complete or partial response to rituximab in combination with chemotherapy, as single-agent maintenance therapy.
- Non-progressing (including stable disease), FL as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy.
- Previously untreated diffuse large B-cell lymphoma (DLBCL) in combination with cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) or other anthracycline-based chemotherapy regimens.
- Previously untreated and previously treated CLL in combination with fludarabine and cyclophosphamide (FC).
- Rituxan Hycela is not indicated for the treatment of non-malignant conditions.